Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations

References

• Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J.28(3), 523–532 (2006).
   PubMed Web of Science ®Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. Respir. Care47(10), 1184–1199 (2002).
   PubMedGoogle Scholar
• Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med.106(2), 196–204 (1987).
   PubMed Web of Science ®Google Scholar
• Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2), CD004403 (2006).
   Google Scholar
• Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA303(20), 2035–2042 (2010).
   PubMed Web of Science ®Google Scholar
• Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med.347(7), 465–471 (2002).
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin. Microbiol. Rev.14(2), 336–363 (2001).
   PubMed Web of Science ®Google Scholar
• Stolz D, Tamm M. Discriminate use of antibiotics for exacerbation of COPD. Curr. Opin. Pulm. Med.15(2), 126–132 (2009).
   PubMed Web of Science ®Google Scholar
• Kruger S, Ewig S, Papassotiriou J et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir. Res.10, 65 (2009).
   PubMed Web of Science ®Google Scholar
• Dandona P, Nix D, Wilson MF et al. Procalcitonin increase after endotoxin injection in normal subjects. J. Clin. Endocrinol. Metab.79(6), 1605–1608 (1994).
   PubMed Web of Science ®Google Scholar
• Linscheid P. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology144(12), 5578–5584 (2003).
   PubMed Web of Science ®Google Scholar
• Kristoffersen KB, Sogaard OS, Wejse C et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission – a randomized trial. Clin. Microbiol. Infect.15(5), 481–487 (2009).
   PubMed Web of Science ®Google Scholar
• Muller B, Peri G, Doni A et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J. Leukoc. Biol.72(4), 643–649 (2002).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev. Anti Infect. Ther.8(5), 575–587 (2010).
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet363(9409), 600–607 (2004).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Thomann R et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA302(10), 1059–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest131(1), 9–19 (2007).
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Wolbers M et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv. Res.7, 102 (2007).
   PubMed Web of Science ®Google Scholar
• Briel M, Schuetz P, Mueller B et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch. Intern. Med.168(18), 2000–2007; discussion 2007–2008 (2008).
   PubMed Web of Science ®Google Scholar
• Lilley R, Feyer AM, Langley J, Wren J. The New Zealand child work-related fatal injury study: 1985–1998. NZ Med. J.117(1194), U891 (2004).
   PubMedGoogle Scholar
• Montero M, Dominguez M, Orozco-Levi M, Salvado M, Knobel H. Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study. Infection37(1), 16–19 (2009).
   PubMedGoogle Scholar
• Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. Journal Respir. Crit. Care Med.174(1), 84–93 (2006).
   PubMed Web of Science ®Google Scholar
• Muller F, Christ-Crain M, Bregenzer T et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest138(1), 121–129 (2010).
   PubMed Web of Science ®Google Scholar
• Roberts RR, Hota B, Ahmad I et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis.49(8), 1175–1184 (2009).
   PubMed Web of Science ®Google Scholar
• Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr. Opin. Pulm. Med, 15(2), 120–125 (2009).
   PubMed Web of Science ®Google Scholar
• Patel AR, Hurst JR, Wedzicha JA. The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin. Respir. Crit. Care Med, 31(3), 267–275 (2010).
   PubMed Web of Science ®Google Scholar
• Bernasconi M, Tamm M, Bingisser R et al. Midregional pro-atrial natriuretic peptide predicts survival in exacerbations of COPD. Chest DOI: 10.1378/chest.10-1353 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Schuetz P, Wolbers M, Christ-Crain M et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit. Care14(3), R106 (2010).
   PubMed Web of Science ®Google Scholar
• Rammaert B, Verdier N, Cavestri B, Nseir S. Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease. Respirology14(7), 969–974 (2009).
   PubMed Web of Science ®Google Scholar